Lifeboat Foundation

The therapy—developed at the University of Nebraska Medical Center (UNMC)—relies on both the immune system to fight key aspects of Alzheimer’s, plus modified cells that zero in on the brain protein plaques that are a hallmark of the disease.

In patients with Alzheimer’s, amyloid-beta protein forms plaques that prevent nerve cells from signaling each other. One theory is that this might cause irreversible memory loss and behavior changes characteristic of Alzheimer’s disease.

The new study was recently published in the journal Molecular Neurodegeneration. Researchers used genetically modified immune-controlling cells called Tregs to target amyloid-beta.

Shared with Dropbox.

A new study published in Nature Cell Biology by Mark Alkema, PhD, professor of neurobiology, establishes an important molecular link between specific B12-producing bacteria in the gut of the roundworm C. elegans and the production of acetylcholine, a neurotransmitter important to memory and cognitive function.

There is growing recognition among scientists that diet and gut microbiota may play an important role in brain health. Changes in the composition of the microbiome have been linked to neurological disorders such as anxiety, depression, migraines and neurodegeneration. Yet, teasing out the cause and effect of individual bacteria or nutrients on brain function has been challenging.

“There are more bacteria in your intestine than you have cells in your body,” said Woo Kyu Kang, PhD, a postdoctoral fellow in the Alkema lab and first author of the current study. “The complexity of the brain, the hundreds of bacterial species that comprise the gut microbiome and the diversity of metabolites make it almost impossible to discern how bacteria impact brain function.”

While dementia is much more common in older adults, hundreds of thousands of people are diagnosed with young-onset dementia (YOD) each year – and an extensive new study sheds some considerable new light on why.

Most previous research in this area has looked at genetics passed down through generations, but here, the team was able to identify 15 different lifestyle and health factors that are associated with YOD risk.

“This is the largest and most robust study of its kind ever conducted,” says epidemiologist David Llewellyn from the University of Exeter in the UK.

A researcher explains the new ketamine trials in patients with depression, and why they show more promise than traditional anti-depressants.

In three patients with Alzheimer’s disease, focused ultrasound was applied with aducanumab therapy. Reduction in amyloid was greater in treated regions than in matched contralateral regions over 6 months. Read the full report:

Original Article from The New England Journal of Medicine — Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease.

“Rather than seeing the organization as a machine, we need to see it as a collection of clever apes.” Psychologist Robin Dunbar’s latest book argues companies are social groups that can’t be perfected like a machine.

What is it about working life that can make us feel so alienated and isolated, and what can we do to prevent it? In The Social Brain: The Psychology of Successful Groups, the evolutionary psychologist Robin Dunbar joins forces with Tracey Camilleri and Samantha Rockey, associate fellows at Oxford’s Saïd Business School, to apply Dunbar’s own scientific discoveries about human cooperation to our work lives. The idea is that, in order to perform our jobs more effectively, we need to go with, and at times go against, the grain of human nature. The authors home in on what makes us best work together, given the central importance of groups throughout our evolutionary history.

Dunbar spent the better part of two decades, starting in the 1970s, studying wild monkeys in Africa to understand why some species develop their own societies. His close contact with our primate cousins gave him a new perspective from which to approach questions about human nature, and that led him, in 1998, to propose the “social brain hypothesis”—the idea that keeping track of who’s who, and cooperating effectively, takes considerable brain power.

Dementia and stroke often have devastating consequences, so patients want to know what they can do to protect themselves against these diseases. A team of clinicians in partnership with patients developed a Brain Care Score (BCS) based on modifiable risk factors identified in past epidemiological studies. In the BCS, weights are assigned to four physical components (i.e., blood pressure, glycosylated hemoglobin, cholesterol, and body-mass index), to five lifestyle elements (i.e., nutrition, alcohol intake, smoking, aerobic activities, and sleep), and to three social factors (i.e., stress, relationships, and purpose in life). Lower scores on the BCS (range, 0–19) predict higher risk.

The team then validated whether the BCS predicted new dementia or stroke in the U.K. Biobank cohort, which consisted of 398,900 people (age range at baseline, 40–69). During average follow-up of nearly 13 years, new dementia or stroke occurred in ≈3% of the cohort. The BCS identified people who were at highest risk for these outcomes. For example, among those who were younger than 50 at baseline, a 5-point higher score predicted 59% lower risk for dementia and 48% lower risk for stroke.

This score could be computed automatically from information already in electronic health records and used to identify risk factors and to engage patients in modifying those risk factors. Whether such scoring would actually lead to lower incidences of dementia and stroke remains to be seen.

Almost exactly one year ago at CES 2023, Qualcomm announced its Snapdragon Ride Flex system-on-chip (SoC) product family. As an expansion of the company’s Snapdragon Digital Chassis product portfolio, the new SoC family is meant to support advanced driver assistance systems (ADAS) as well as digital cockpit and infotainment applications spanning from entry level to premium vehicles. At the time, Qualcomm announced that the Ride Flex SoC was sampling with an expected start of production in early 2024. It’s now early 2024 and CES is about to kick off again. Tirias Research is expecting to hear an update on the product family next week. We anticipate the update will include, at the very least, some of the partners who will be bringing the Ride Flex SoCs to market in production volumes this year and into 2025. Given Qualcomm’s track record for hitting their estimated timelines, we felt that a re-cap of the product family is warranted leading up to next week’s anticipated update.

“Flex-ing” Resources to Support Mixed Criticality and Multiple Tiers

The Snapdragon Ride Flex is actually two monolithically integrated 4nm SoCs – a primary SoC and what Qualcomm are calling a Safety Island SoC. The primary SoC consists of a Kryo Gen 6 Arm v8.2 central processing unit (CPU) with integrated L3 cache, an Adreno 663 graphics processing unit (GPU), a Hexagon neural processing unit (NPU), a Spectra 690 image signal processing (ISP), two Adreno display processing units (DPUs) for multiple high-resolution display support and associated memory and I/O interconnects. This part of the SoC is Automotive Safety Integrity Level (ASIL) B certified. The Safety Island SoC, which is ASIL-D certified, consists of a multi-core real-time CPU with enhanced error managements support and isolated memory and peripherals. ASIL is a risk classification methodology established under ISO 26,262 from the International Organization for Standardization which defines functional safety for road vehicles.